Inventor · disambiguated record
Alexander Birkmann
Also filed as: BIRKMANN ALEXANDER
11 granted patents·4 pending applications·47 citations·filing 2009–2024
88Inventor score
Top patents by PatentIndex Score
15 records- 0193US9119786B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS GMBH & CO KG·Filed 2013·Granted Sep 1, 2015·15 cites·19 claims
- 0292US10137117B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Nov 27, 2018·6 cites·22 claims
- 0392US9592225B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI-INFECTIVE CURES GMBH·Filed 2015·Granted Mar 14, 2017·8 cites·22 claims
- 0491US9889124B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2015·Granted Feb 13, 2018·6 cites·30 claims
- 0588US11021474B2N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Jun 1, 2021·4 cites·11 claims
- 0686US12070451B2Sulfate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereofAICURIS GMBH & CO KG·Filed 2022·Granted Aug 27, 2024·1 cites·12 claims
- 0783US11266636B2Maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes virusesAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Mar 8, 2022·2 cites·15 claims
- 0880US9340535B2N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrateAICURIS GMBH & CO KG·Filed 2012·Granted May 17, 2016·5 cites·25 claims
- 0978US2025042893A1N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2024·Application pending·0 cites
- 1077US2024350468A1Maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereofAICURIS GMBH & CO KG·Filed 2024·Application pending·0 cites
- 1172USRE49697ECrystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2020·Granted Oct 17, 2023·0 cites·32 claims
- 1270US12152022B2N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2021·Granted Nov 26, 2024·0 cites·24 claims
- 1354US11213516B2Intravaginally applicable devices comprising antiviral compoundsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2018·Granted Jan 4, 2022·0 cites·19 claims
- 1448US2010022527A1Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseasesAICURIS GMBH & CO KG·Filed 2009·Application pending·0 cites
- 1547US2022401553A1Parapoxvirus for conditioning for and treatment of coronavirus infectionsAICURIS GMBH & CO KG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexander Birkmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →